Bharat Parenterals Ltd reported a standalone revenue of Rs. 318.7 crores for FY25, a 19.8% increase from FY24, with a consolidated revenue of Rs. 352.28 crores, reflecting a 32% growth, despite a significant drop in EBITDA margins due to increased costs at its subsidiary.